Context: Although telomeres are "sacrificial" DNA without any necessary genetic content, each time a cell divides, telomeres get shorter. When they decrease to a critical length, cell division ceases and cells becomes inactive or "senescent" or die. This process is associated with aging. To some extent, the process of telomere shortening is slowed by the enzyme telomerase, whose purpose it is to add telomere length to DNA. Certain nutraceuticals have been shown to activate telomerase, and extend telomere length. While this will not make cells immortal, it may extend their lifespan.
Introduction
There are multiple theories on aging which may be classified under the general headings of programmed aging or unprogrammed aging. Programmed aging may be described as aging resulting from genetically programmed factors. Unprogrammed aging may be described as aging resulting from molecular damage to normal body cells and molecules. According to Spence [1] , a compelling argument can be made for some manner of programmed aging since aging begins at birth and each species seems to have its own average lifespan. The telomere theory of aging falls into this classi ication.
As cells age, they lose a certain number of base pairs of DNA, known as telomeres, from the end of each chromosome every time cell division takes place. Although the telomeres are "sacrificial" DNA without any necessary genetic content, there is still a problem. When these telomeres have decreased to a critical length, cell division ceases; although cell senescence may continue for a time [2] . This finite ability to replicate is known as the "Hayflick limit, " and has been seen in normal cultured human and animal cells [3] . Fibroblast cells taken from adults would only divide about 20 times in vitro, although this limit is rarely, if ever, reached in the body [1] . Summarily, each time a cell divides, telomeres get shorter. When they get too short, the cell can no longer divide and becomes inactive or "senescent" or dies. This process is associated with aging [2] .
To some extent, the process of telomere shortening is slowed by the enzyme telomerase, whose purpose it is to add telomere length to DNA [2] . Telomerase is found in some cells (e.g., germ cells and stem cells), which must divide continually to perform their functions. By promoting telomerase activity, it is possible to increase telomere length and consequently extend the period of time that cellular division can take place. While this will not make cells immortal, it may extend their lifespan [3] .
Of particular interest is the fact that certain nutraceuticals have been shown to activate telomerase, and extend telomere length. One 
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such nutraceutical is vitamin D. In a double blind, randomized and placebo-controlled clinical trial [4] , Zhu et al. examined the effect of vitamin D supplementation on telomerase activity in 37 overweight African American adults. Subjects received a placebo or the equivalent of 2000 IU oral vitamin D3 supplementation daily for 16 weeks. Results showed that in the vitamin D group, telomerase activity significantly increased by 19.2% (P<0.0001). The significance persisted after controlling for age, sex and body mass index. Telomerase activity in the placebo group did not change.
This is consistent with research [5] by Richards et al. which showed that higher serum vitamin D concentrations in 2160 women were positively significantly associated with leukocyte telomere length (P=0.001), and the difference in telomere length between those with the highest and lowest vitamin D intake was 107 base pairs, which is equivalent to 5 years of telomeric aging. Similarly, human research has demonstrated longer telomere length in association with higher consumption of tea [6] , lutein, zeaxanthin, and vitamin C [7] , as well as several other vitamins and minerals [8] .
As a result of these, and other studies demonstrating the telomerase activating and/or telomere lengthening effects of nutraceuticals, a multivitamin was formulated to extend telomere length (TeloVite, West-Martin Longevity) and a pilot study was conducted to examine the efficacy of the formulation in extending telomere length, and ascertain the viability of conducting a larger, randomized, controlled trial in the future.
Materials and Methods

Participants
The 90-day study was an open-label pilot. Generally healthy men and women older than 18 years were deemed eligible for participation. Subjects were recruited between February 1, 2013, and June 1, 2013, from a video solicitation on the website of West-Martin Longevity. All eligible patients were screened by the principal investigator. All volunteers had to have stable health (i.e., no hospitalizations, medical procedures, or changes in medications for at least 30 d prior to enrollment). Exclusion criteria included (1) having a life expectancy of less than 6 months, (2) being pregnant or currently breastfeeding, (3) being unwilling or unable to complete 90-days of supplementation with Telovite, or (4) currently using any other dietary supplement.
Procedures
After written informed consent was obtained, baseline assessments were completed, including each participant's (1) demographics; (2) medical history; (3) current medications and dosages; (4) height; (5) weight; and (6) BMI. Subjects received individualized instructions regarding the use of Telovite. DNA samples from buccal swabs were obtained at baseline, and at day 90.
Intervention
All subjects received a 90-day supply of Telovite (Table 1) , and were instructed to take one table, three times daily with meals. They were also instructed not to change their current dietary practices or exercise routine.
Amount Per 3 Tablets:
Vitamin A (as acetate, beta-carotene) 5000 IU 
Outcomes
The outcome was absolute telomere length, measured with a simple and reproducible, quantitative real-time polymerase chain reaction (qPCR) method described by O'Callaghan and Fenech, using a DNA sample from a buccal (inner-cheek) swab of each subject [9] . The qPCR analysis was conducted at Titanovo Labs (North Carolina).
Fifteen subjects were recruited for the pilot study. Due to attrition and non-compliance, ten subjects completed the protocol and were included in the results. Results were that 8 out of the 10 subjects had notable increases in telomere length, whereas the remaining two subjects had a decrease in telomere length. The reason for the decrease in telomere length in the 2 subjects is unclear ( The mean increase in telomere length for the eight subjects was 77.26%. When all 10 subjects are included, the mean increase in telomere length was 55.86%.
Discussion
The purpose of this pilot study was to examine the efficacy of the Telovite formulation in extending telomere length, and ascertain the viability of conducting a larger, randomized, controlled trial in the future. While there were an insufficient number of subjects to adequately power the study and calculate statistical significance, the results of this open-label pilot study are promising, and indicate that 90 days of supplementation with Telovite was effective in lengthening telomeres in the majority of subjects tested.
Conclusion
The current pilot trial demonstrated the efficacy of Telovite in lengthening the telomeres of 8 out of the 10 subjects. These findings suggest that is worthwhile to conduct a larger, randomized, controlled trial to measure the telomere lengthening effects of Telovite, giving further consideration to the reasons behind the lack of telomere lengthening in the minority of subjects.
